Steady Expansion Forecast for Implantable Neurostimulation Devices Market, Projected to Reach $8.86 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Implantable Neurostimulation Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for implantable neurostimulation devices has seen a swift development lately. The market is expected to surge from $5.02 billion in 2024 to $5.62 billion in 2025, presenting a compound annual growth rate (CAGR) of 11.8%. The notable expansion during the past years has been largely due to factors such as a growing appetite for non-drug treatments, increased demand for minimally invasive operations, rising numbers of elderly people, a broadening scope of psychiatric disorders, and a heightened prevalence of chronic illnesses.

Implantable Neurostimulation Devices Market Size Forecast: What's the Projected Valuation by 2029?
Over the coming years, the market for implantable neurostimulation devices is predicted to experience rapid expansion, with projections indicating a rise to $8.86 billion by 2029 at an annual growth rate of 12.1%. This surge during the forecast timeframe is primarily due to an increase in neurological disorders, lifestyle-related diseases, rising awareness, a spike in spinal cord injuries, and higher healare expenditure. Future market trends include the application of sensing technology, advancements in neurostimulation technologies, the introduction of high-tech products, the integration of closed-loop systems, and the incorporation of wireless technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/implantable-neurostimulation-devices-global-market-report

What Are the Drivers Transforming the Implantable Neurostimulation Devices Market?
The anticipated surge in neurological conditions is predicted to fuel the expansion of the implantable neurostimulation device market. Neurological disorders, which encompass various issues that disrupt the structure or functionality of the nervous system, lead to diverse symptoms such as cognitive impairments, seizures, and paralysis. The increase in risk factors like trauma, developmental irregularities, and high blood pressure contribute to a higher rate of detecting neurological disorders. Implantable neurostimulation devices come into play when standard treatments fail to improve neurological disorders, as they regulate nerve activity and alleviate symptoms. For example, the Alzheimer's Association, a US-based voluntary health organization, estimates that in 2024, about 6.9 million Americans over the age of 65 will be afflicted by Alzheimer's, with 73% above 75 years old. This figure is predicted to soar to 12.7 million by 2050. As a result, the escalating prevalence of neurological disorders augurs well for the development of the implantable neurostimulation device market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19520&type=smp

What Trends Will Shape the Implantable Neurostimulation Devices Market Through 2029 and Beyond?
Leading companies in the implantable neurostimulation devices marketplace are concentrating on the creation of sophisticated products, such as spinal cord stimulation (SCS) systems, for the treatment of chronic pain conditions. A SCS system, a type of medical device, employs electrical pulses to regulate nerve activity within the spinal cord, aiming to alleviate chronic pain and enhance patients' livelihoods when other interventions prove unsuccessful. For example, in December 2022, US-based company Abbott, specializing in medical devices, made public their receipt of U.S. Food and Drug Administration (FDA) approval for their Eterna spinal cord stimulation (SCS) system. The Eterna SCS, the smallest rechargeable spinal cord stimulator on the market, was designed with optimum daily comfort in mind. Abbott's unique BurstDR stimulation technology is a key feature, replicating natural brain activity for optimal pain alleviation and preferred by 87% of patients compared to traditional tingling stimulation. Eterna offers convenience through its scarce recharging needs, only requiring approximately five annual charges due to the Xtend energy technology. It accommodates whole-body MRI scans through TotalScan technology and is built for adaptability to future developments without the need for replacement. Also, Abbott's integration of a mobile app allows for immediate monitoring of battery lifespan and charging status on iPhone devices.

Which Segments in the Implantable Neurostimulation Devices Market Offer the Most Profit Potential?
The implantable neurostimulation devices market covered in this report is segmented -

1) By Type: Spinal Cord Stimulation (SCS), Gastric Electric Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), Vagus Nerve Stimulation (VNS), Other Types
2) By Application: Pain Management, Parkinson's Disease, Urinary And Fecal Incontinence, Epilepsy, Gastroparesis, Other Applications
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Spinal Cord Stimulation (SCS): Rechargeable SCS Devices, Non-Rechargeable SCS Devices
2) By Gastric Electric Stimulation (GES): Implantable Gastric Stimulators, Adjustable Gastric Stimulators
3) By Deep Brain Stimulation (DBS): DBS Devices for Movement Disorders, DBS Devices for Psychiatric Disorders
4) By Sacral Nerve Stimulation (SNS): SNS Devices for Urinary Incontinence, SNS Devices for Fecal Incontinence
5) By Vagus Nerve Stimulation (VNS): VNS Devices for Epilepsy, VNS Devices for Depression
6) By Other Types: Peripheral Nerve Stimulation (PNS), Cortical Stimulation Devices, Novel Neurostimulation Technologies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19520&type=smp

Which Firms Dominate the Implantable Neurostimulation Devices Market by Market Share and Revenue in 2025?
Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Dignity Health, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., CURE Epilepsy, Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Pain Management NYC, Curonix LLC

Which Regions Offer the Highest Growth Potential in the Implantable Neurostimulation Devices Market?
North America was the largest region in the implantable neurostimulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19520

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.